Obsidan (Propranolol Hydrochloride)

Propranolol Hydrochloride, the active ingredient in Obsidan, is a beta‑blocker presented as a tablet for oral use. It is employed to manage cardiovascular conditions such as hypertension, angina, and certain arrhythmias in adult patients.

GNH USA supplies Obsidan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Obsidan (propranolol) acts on the cardiovascular system to control heart rate and blood pressure.

- Hypertension: helps lower elevated blood pressure and reduce cardiovascular risk. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. - Cardiac arrhythmias: stabilizes abnormal heart rhythms such as supraventricular tachycardia. - Migraine prophylaxis: reduces frequency and severity of migraine attacks. - Essential tremor: diminishes tremor amplitude in the hands. - Portal hypertension: lowers portal venous pressure in patients with cirrhosis.

Propranolol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue - Dizziness - Cold extremities - Gastrointestinal upset - Sleep disturbances - Bradycardia

Serious or Rare Side Effects: - Severe bronchospasm - Hypotension - Heart block - Acute heart failure - Depression or mood changes - Allergic skin reactions

When prescribing Obsidan, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate for bradycardia or heart block before initiation. - Respiratory status: avoid in patients with active asthma or severe COPD. - Diabetes monitoring: beta‑blockade can mask hypoglycaemia symptoms. - Thyroid disease: use cautiously in hyperthyroid patients. - Drug discontinuation: taper gradually to prevent rebound tachycardia. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Propranolol interacts with several medicines that can alter its effectiveness or safety.

Major Interactions (Avoid): - Calcium channel blockers (e.g., verapamil, diltiazem): increased risk of bradycardia and AV‑block. - Antidiabetic agents (insulin, sulfonylureas): enhanced hypoglycaemic effect. - Non‑selective MAO‑inhibitors: Moderate Interaction ​​      t   t  t

t  t"""